CN111971562A - 法伯病标志物及其用途 - Google Patents

法伯病标志物及其用途 Download PDF

Info

Publication number
CN111971562A
CN111971562A CN201980008575.9A CN201980008575A CN111971562A CN 111971562 A CN111971562 A CN 111971562A CN 201980008575 A CN201980008575 A CN 201980008575A CN 111971562 A CN111971562 A CN 111971562A
Authority
CN
China
Prior art keywords
cd11b
mhcii
subject
cells
mid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980008575.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·科克里
B·桑佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arthur Reagan
Original Assignee
Real Vanguard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Real Vanguard filed Critical Real Vanguard
Priority to CN202311688835.6A priority Critical patent/CN118112249A/zh
Publication of CN111971562A publication Critical patent/CN111971562A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980008575.9A 2018-03-27 2019-03-22 法伯病标志物及其用途 Pending CN111971562A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311688835.6A CN118112249A (zh) 2018-03-27 2019-03-22 法伯病标志物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
US62/648,775 2018-03-27
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311688835.6A Division CN118112249A (zh) 2018-03-27 2019-03-22 法伯病标志物及其用途

Publications (1)

Publication Number Publication Date
CN111971562A true CN111971562A (zh) 2020-11-20

Family

ID=66530353

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980008575.9A Pending CN111971562A (zh) 2018-03-27 2019-03-22 法伯病标志物及其用途
CN202311688835.6A Pending CN118112249A (zh) 2018-03-27 2019-03-22 法伯病标志物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311688835.6A Pending CN118112249A (zh) 2018-03-27 2019-03-22 法伯病标志物及其用途

Country Status (16)

Country Link
US (2) US20190302126A1 (cg-RX-API-DMAC7.html)
EP (1) EP3775924A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021516757A (cg-RX-API-DMAC7.html)
KR (2) KR20240111011A (cg-RX-API-DMAC7.html)
CN (2) CN111971562A (cg-RX-API-DMAC7.html)
AU (1) AU2019244477A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020016435A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090354A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002105A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010043A2 (cg-RX-API-DMAC7.html)
IL (2) IL311212A (cg-RX-API-DMAC7.html)
MX (1) MX2020008377A (cg-RX-API-DMAC7.html)
PH (1) PH12020551206A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020119065A (cg-RX-API-DMAC7.html)
SG (1) SG11202007508TA (cg-RX-API-DMAC7.html)
WO (1) WO2019186272A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117647649A (zh) * 2023-08-15 2024-03-05 迈健医药科技无锡有限公司 一种免疫细胞全维分析的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B S HANNA等: "Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo", ，,", LEUKEMIA, pages 570 - 579 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117647649A (zh) * 2023-08-15 2024-03-05 迈健医药科技无锡有限公司 一种免疫细胞全维分析的方法

Also Published As

Publication number Publication date
BR112020016435A2 (pt) 2020-12-15
KR20200136367A (ko) 2020-12-07
MX2020008377A (es) 2020-09-25
CO2020010043A2 (es) 2020-11-10
RU2020119065A (ru) 2022-04-27
PH12020551206A1 (en) 2021-04-19
EP3775924A1 (en) 2021-02-17
SG11202007508TA (en) 2020-09-29
CL2020002105A1 (es) 2020-12-04
CN118112249A (zh) 2024-05-31
JP2021516757A (ja) 2021-07-08
US20190302126A1 (en) 2019-10-03
IL311212A (en) 2024-05-01
WO2019186272A1 (en) 2019-10-03
US20210199670A1 (en) 2021-07-01
AU2019244477A1 (en) 2020-06-25
CA3090354A1 (en) 2019-10-03
JP2023159164A (ja) 2023-10-31
KR20240111011A (ko) 2024-07-16
IL276420A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
JP2023159164A (ja) ファーバー病マーカーおよびその使用
US20250170225A1 (en) Compositions and methods for treating farber disease
US20230123505A1 (en) Methods for treating farber disease
US6562574B2 (en) Association of protein kinase C zeta polymorphisms with diabetes
US6458541B1 (en) BDNF polymorphism and association with bipolar disorder
JP2007530069A (ja) イオンチャネル
JP2007530069A6 (ja) イオンチャネル
WO2001046415A1 (en) Novel tachykinin-like polypeptides and use thereof
JP2008506361A (ja) イオンチャネル
JP2002541440A (ja) 記憶の固定を調節する方法及び組成物
HK40105998A (en) Compositions and methods for treating farber disease
US20050147969A1 (en) Genes associated with mast cell activation
HK1079690A (en) Osteopontin, oligodendrocytes and myelination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211203

Address after: Delaware

Applicant after: Arthur Reagan

Address before: Basel, Switzerland

Applicant before: Real Vanguard

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201120

WD01 Invention patent application deemed withdrawn after publication